What is iovera°?
iovera° offers a non-opioid pain relief treatment that leverages cryoneurolysis technology to deliver targeted, drug-free relief for conditions such as osteoarthritis and post-surgery recovery. The FDA-cleared treatment is adaptable for various healthcare settings, including hospitals and outpatient clinics, addressing pain in areas like the knee, hip, shoulder, and spine. By applying extreme cold to peripheral nerves, iovera° effectively blocks pain signals for up to 90 days, providing a novel alternative to traditional pain management methods.
How much funding has iovera° raised?
iovera° has raised a total of $72.6M across 6 funding rounds:
Debt
$2.2M
Private Equity
$18.8M
Private Equity
$32.7M
Private Equity
$10M
Debt
$8.4M
Unspecified
$556K
Debt (2010): $2.2M, investors not publicly disclosed
Private Equity (2011): $18.8M, investors not publicly disclosed
Private Equity (2012): $32.7M supported by DeNovo Ventures, Saratoga Ventures, L.P., Medicis Capital, and Accuitive Medical Ventures
Private Equity (2013): $10M featuring Medicis Capital Group, Valiance Asset Management Limited, DeNovo Ventures, and Accuitive Medical Ventures
Debt (2014): $8.4M backed by NMT Capital
Unspecified (2017): $556K, investors not publicly disclosed
Key Investors in iovera°
NMT Capital
NMT Capital is a private equity firm with a global focus, managing investments across Europe and the US. They specialize in sectors including medical technology and life sciences, offering strategic capital and consulting for companies in need of growth or acquisition.
Medicis Capital Group
MEDICIS provides strategic and operational expertise in the healthcare sector, focusing on midsized companies in Pharma, Biotech, MedTech, Diagnostics, and Healthcare Services, particularly for strategic growth plans in Western Europe.
DeNovo Ventures
Denovo Ventures is a full-service firm specializing in Enterprise Hosting/Cloud Computing, Application Managed Services, and Managed Disaster Recovery, with a history of supporting technology businesses.
What's next for iovera°?
With the recent major strategic investment and a substantial total funding amount of $72.6M, iovera° is well-positioned for its next phase of growth. The company's focus on cryoneurolysis technology for drug-free pain relief aligns with the increasing demand for non-addictive treatment options. Future strategic initiatives will likely involve expanding clinical applications, scaling manufacturing and distribution, and further penetrating key healthcare markets. The company's trajectory suggests a continued emphasis on innovation and market expansion within the pain management landscape.
See full iovera° company page
